Antinociceptive effect of topiramate in models of acute pain and diabetic neuropathy in rodents

Life Sci. 2009 Jan 16;84(3-4):105-10. doi: 10.1016/j.lfs.2008.11.005. Epub 2008 Nov 17.

Abstract

This study assesses the antinociceptive effect induced by different dosages of topiramate (TP), an anticonvulsant drug that is orally administered in models of neuropathic pain and acute pain in rats and mice, respectively. Orally administered TP (80 mg/Kg) in mice causes antinociception in the first and second phases of a formalin test, while in doses of 20 and 40 mg/Kg it was only effective in the second phase. TP (80 mg/Kg, p.o) also exhibited antinociceptive action in the hot plate test, however, it did not have an effect in the capsaicin test in mice, nor in the model of neuropathic pain in diabetic rats. The antinociceptive effect caused by TP (80 mg/Kg, p.o) in the formalin test was reversed by prior treatment with naloxone (opioid antagonist), but not with glibenclamide (antagonist of the potassium channel), ondansetron (antagonist of the serotonin 5HT3 receptor) or cyproheptadine (antagonist of the serotonin 5HT2A receptor).The data show that TP has an important antinociceptive effect in the models of nociception induced by chemical (formalin) or thermal (hot plate) stimuli, and that the opioid system plays a part in the antinociceptive effect, as shown by formalin.

MeSH terms

  • Acute Disease
  • Analgesics / therapeutic use*
  • Animals
  • Diabetic Neuropathies / drug therapy*
  • Disease Models, Animal
  • Fructose / analogs & derivatives*
  • Fructose / therapeutic use
  • Male
  • Mice
  • Pain / drug therapy*
  • Pain Measurement
  • Receptor, Serotonin, 5-HT2A / physiology
  • Receptors, Serotonin, 5-HT3 / physiology
  • Topiramate

Substances

  • Analgesics
  • Receptor, Serotonin, 5-HT2A
  • Receptors, Serotonin, 5-HT3
  • Topiramate
  • Fructose